Geneva, Sept. 23 -- International Clinical Trials Registry received information related to the study (NCT07170150) titled 'A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease' on Sept. 10.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Hoffmann-La Roche
Condition:
Alzheimers Disease
Intervention:
Drug: Trontinemab
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: October 27, 2025
Target Sample Size: 800
To know more, visit https://clinicaltrials.gov/study/NCT07170150
Disclai...